PyInvesting

Market research

LALPATHLAB.NSE Dr. Lal PathLabs Limited

NSE INR Healthcare

Latest close

2,008.80 —

As of Nov 12, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
337B
P/E ratio
57.83
Analyst target
2210.1538
Dividend yield
0.8%
Beta
0.2

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Dr. Lal PathLabs Limited is currently in a long term uptrend where the price is trading 36.3% above its 200 day moving average.

From a valuation standpoint, the stock is 244.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.5.

Dr. Lal PathLabs Limited's total revenue rose by 38.0% to $5B since the same quarter in the previous year.

Its net income has increased by 74.7% to $945M since the same quarter in the previous year.

Based on the above factors, Dr. Lal PathLabs Limited gets an overall score of 3/5.